Skip to content
Dx

ICD-10-CM 2027 diagnosis code

D69.11Glanzmann thrombasthenia

✓ Billable / specificNew for 2027

D69.11 is a valid, billable ICD-10-CM code for glanzmann thrombasthenia. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS, effective October 1, 2026. Updated September 29, 2026. About our data

About D69.11

D69.11 is the ICD-10-CM diagnosis code for Glanzmann thrombasthenia. It belongs to category D69 (purpura and other hemorrhagic conditions), block D65-D69 (coagulation defects, purpura and other hemorrhagic conditions) and chapter 3 (diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within D69.1 (qualitative platelet defects), D69.11 is specifically for Glanzmann thrombasthenia. Related codes cover other qualitative platelet defects (D69.19).

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 813 (Coagulation Disorders, relative weight 1.5257), in MDC 16 (Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It was added in FY2027, effective October 1, 2026.

Coding notes

Applicable toConditions and synonyms classified to this code
  • Glanzmann's disease
  • Thromboasthenia (hemorrhagic) (hereditary)

Notes that apply from higher levels

Instructions written at a parent level also apply to D69.11.

› From D69.1 Qualitative platelet defects
Excludes1
  • hemolytic-uremic syndrome (D59.3-)
Excludes2
  • von Willebrand disease (D68.0-)
› From D69 Purpura and other hemorrhagic conditions
Excludes1
  • benign hypergammaglobulinemic purpura (D89.0)
  • cryoglobulinemic purpura (D89.1)
  • essential (hemorrhagic) thrombocythemia (D47.3)
  • hemorrhagic thrombocythemia (D47.3)
  • purpura fulminans (D65)
  • thrombotic thrombocytopenic purpura (M31.19)
  • Waldenström hypergammaglobulinemic purpura (D89.0)

Broader instructions also apply from Chapter 3: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism.

Alphabetic index entries

6 entries

Terms in the official ICD-10-CM index that lead to D69.11.

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

MDC 16 · Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2027 (effective 10/1/2026): Added

Common questions about D69.11

Is D69.11 billable?

Yes. D69.11 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can D69.11 be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict D69.11 as a principal diagnosis.

Is D69.11 a CC or MCC?

No. D69.11 is neither a CC nor an MCC under MS-DRG v44.0.

What DRG does D69.11 group to?

D69.11 is used in the MS-DRG v44.0 logic for MS-DRG 813 (Coagulation Disorders). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.

Did D69.11 change for 2027?

Yes. For FY2027 (effective October 1, 2026) it was added to the code set.